J. Kastelein

发表

Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease

Thomas W. Mühleisen, Benjamin J. Wright, C. Gieger, 2011, Nature Genetics.

Comprehensive Whole-Genome and Candidate Gene Analysis for Response to Statin Therapy in the Treating to New Targets (TNT) Cohort

D. Cox, D. Hinds, Johnf . Thompson, 2009, Circulation. Cardiovascular genetics.

Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study

L. Thal, C. Lewis, L. Kuller, 2004, JAMA.

Prolactin Levels and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women

N. Wareham, K. Khaw, J. Kastelein, 2009, Circulation. Cardiovascular genetics.

Differential leucocyte count and the risk of future coronary artery disease in healthy men and women: the EPIC‐Norfolk Prospective Population Study

N E Day, S A Bingham, J W Jukema, 2007, Journal of internal medicine.

Common variants associated with plasma triglycerides and risk for coronary artery disease

Tanya M. Teslovich, Ross M. Fraser, May E. Montasser, 2013, Nature Genetics.

Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study

P. Talmud, N. Wareham, K. Khaw, 2011, Journal of Lipid Research.

Ext1 heterozygosity causes a modest effect on postprandial lipid clearance in humans[S]

J. Kastelein, M. Nieuwdorp, J. Esko, 2015, Journal of Lipid Research.

Molecular genetics and gene expression in atherosclerosis.

P. Doevendans, W. Spiering, J. Kastelein, 2001, International journal of cardiology.

Variants of Toll-Like Receptor 4 Modify the Efficacy of Statin Therapy and the Risk of Cardiovascular Events

A. Zwinderman, R. Peters, P. Reitsma, 2003, Circulation.

Lipid parameters for measuring risk of cardiovascular disease

J. Kastelein, S. Boekholdt, B. Arsenault, 2011, Nature Reviews Cardiology.

Measurement of carotid intima–media thickness to assess progression and regression of atherosclerosis

M. Bots, E. Groot, M. C. Meuwese, 2008, Nature Clinical Practice Cardiovascular Medicine.

C-Reactive Protein, Fatal and Nonfatal Coronary Artery Disease, Stroke, and Peripheral Artery Disease in the Prospective EPIC-Norfolk Cohort Study

Diederik F Van Wijk, N. Wareham, K. Khaw, 2013, Arteriosclerosis, thrombosis, and vascular biology.

Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy.

M. Trip, F. Akdim, D. Tribble, 2010, Journal of the American College of Cardiology.

The genetics of high-density lipoprotein metabolism: clinical relevance for therapeutic approaches.

J. Kastelein, E. Stroes, G. Hovingh, 2009, The American journal of cardiology.

Cholesteryl Ester Transfer Protein ( CETP ) Inhibition Beyond Raising High-Density Lipoprotein Cholesterol Levels Pathways by Which Modulation of CETP Activity May Alter Atherogenesis

J. Kastelein, S. Boekholdt, E. Stroes, 2006 .

Carriers of the PCSK9 R46L Variant Are Characterized by an Antiatherogenic Lipoprotein Profile Assessed by Nuclear Magnetic Resonance Spectroscopy—Brief Report

N. Wareham, K. Khaw, J. Kastelein, 2017, Arteriosclerosis, thrombosis, and vascular biology.

Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk.

P. Barter, D. Waters, J. Kastelein, 2017, Journal of clinical lipidology.

High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies.

Christina Lindahl, Nicholas J Wareham, Mogens Lytken Larsen, 2008, Journal of the American College of Cardiology.

Cox proportional hazards models have more statistical power than logistic regression models in cross-sectional genetic association studies

E. Steyerberg, A. Janssens, M. Eijkemans, 2008, European Journal of Human Genetics.

Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated Patients A Meta-Analysis

P. Ridker, P. Amarenco, D. Demicco, 2013 .

Meta-analysis of genome-wide association studies of HDL cholesterol response to statins

Joshua C Denny, Wei-Qi Wei, Fredrik Nyberg, 2016, Journal of Medical Genetics.

Lipodystrophy associated with treatment of HIV‐1 infection

P. Reiss, J. Kastelein, M. van der Valk, 2003 .

Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing?

J. Kastelein, J. Hoekstra, J. H. von der Thüsen, 2011, Diabetes, obesity & metabolism.

Physical inactivity, abdominal obesity and risk of coronary heart disease in apparently healthy men and women

J. Després, K. Khaw, J. Kastelein, 2010, International Journal of Obesity.

High-Dose Statin Therapy in Patients With Stable Coronary Artery Disease: Treating the Right Patients Based on Individualized Prediction of Treatment Effect

P. Ridker, S. Boekholdt, D. Demicco, 2013, Circulation.

High-dose Statin Therapy in Patients with Stable Coronary Artery Disease: Treating the Right Patients Based on Individualized Prediction of Treatment Effect Running Title: Dorresteijn Et Al.; High-dose Statins in Individual Patients

N. Cook, P. Ridker, J. Kastelein, 2022 .

Comparison between gradient gel electrophoresis and nuclear magnetic resonance spectroscopy in estimating coronary heart disease risk associated with LDL and HDL particle size.

J. Després, N. Wareham, K. Khaw, 2010, Clinical chemistry.

Serum Lipoprotein Lipase Concentration and Risk for Future Coronary Artery Disease: The EPIC-Norfolk Prospective Population Study

N. Day, R. Luben, N. Wareham, 2005, Arteriosclerosis, thrombosis, and vascular biology.

Genetic aspects of restenosis after percutaneous coronary interventions: towards more tailored therapy.

J. Jukema, J. Kastelein, S. Pimstone, 2001, European heart journal.

Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study

H. Büller, E. Sijbrands, J. Kastelein, 2004, JAMA.

Normalization of metabolic syndrome using fenofibrate, metformin or their combination

M. Nieuwdorp, E. Stroes, E. Stroes, 2007, Diabetes, obesity & metabolism.

Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study

D. Rader, J. Kastelein, S. Nissen, 2016, European heart journal.

Reduced fecal sterol excretion in subjects with familial hypoalphalipoproteinemia.

J. Kastelein, E. Stroes, F. Kuipers, 2009, Atherosclerosis.

Inflammatory biomarkers and the prediction of coronary events among people at intermediate risk: the EPIC-Norfolk prospective population study

K. Khaw, S. Boekholdt, N. Wareham, 2009, Heart.

HDL particle size and the risk of coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study.

J. Després, N. Wareham, K. Khaw, 2009, Atherosclerosis.

Metabolic dyslipidemia and risk of future coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study.

J. Després, N. Wareham, K. Khaw, 2010, International journal of cardiology.